AI Earnings Predictions for Jasper Therapeutics Inc. (JSPR)

EX-99.1

2 ea030204901ex99-1.htm

PRESS RELEASE, DATED AUGUST 14, 2026

Exhibit 99.1

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Completed a concurrent PIPE financing raising $132 million in gross proceeds

REDWOOD CITY, Calif., August 14, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update.

“We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission of developing a differentiated portfolio of innovative therapies for patients with significant immune-mediated diseases. Supported by our recent $132 million financing led by leading life sciences investors, we believe that we have sufficient capital to fund planned operations through the second half of 2028. We plan to advance development of our lead asset KP-104, a novel dual inhibitor of the complement cascade, in multiple indications, progress briquilimab towards a potential BLA, and to commence first in human studies for KP-701,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “The combined company now has access to significant resources in the United States and China, which we believe will allow us to rapidly advance our portfolio across multiple diseases of unmet need.”

Corporate Updates for Second Quarter 2026 and Recent Weeks

●On July 16, 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.

●Concurrently with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other leading life science investors. The private placement resulted in total gross proceeds of approximately $132 million.

●The combined company is focused on advancing its consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven disorders, including:

oKP-104 (Vensobafusp alfa), a Phase 2/3 ready, potentially best-in-disease, bifunctional biologic targeting

both the alternative and terminal pathways within the complement cascade for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and high unmet need nephrology disorders. KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026. Based on previous, positive results in treatment-naïve PNH, the combined company is also planning for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and plans to announce next steps for development in PNH in the first half of 2027;

oBriquilimab, a late-stage, potentially best-in-class anti-KIT antibody with broad therapeutic utility across multiple transplant and immunologic indications. Based on positive, long-term data generated in SCID, the combined company is progressing its efforts towards a pre-BLA meeting with the FDA and expects to announce next steps in the first quarter of 2027; and

oKP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The combined company expects to file a clinical trial application (CTA) and/or an investigational new drug (IND) for Phase 1 evaluation in the first quarter of 2027.

Second Quarter Fiscal 2026 Financial Results

●Cash and cash equivalents as of June 30, 2026, totaled $7.3 million.

●Research and development expense for the three months ended June 30, 2026, was $5.1 million.

●General and administrative expense for the three months ended June 30, 2026, was $4.1 million.

●Jasper reported a net loss of $2.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.10 for the three months ended June 30, 2026.

About Jasper

The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditi

EX-99.1

2 ea029079201ex99-1.htm

PRESS RELEASE, DATED MAY 14, 2026

Exhibit 99.1

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.

“In recent months, we have continued to advance the briquilimab development program in CSU.” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our positive clinical data update in January, we have conducted an analysis of the full data package from BEACON, SPOTLIGHT and the open-label extension study to drive the selection of two active dosing regimens to evaluate in our Phase 2b study. In parallel we have also updated and refiled the Phase 2b protocol with the FDA as we work to secure additional funding to enable commencement of the study in the second half of this year as planned.”

Highlights for First Quarter 2025 and Recent Weeks

●Refiled an updated Phase 2b protocol with the FDA for the planned Phase 2b study of briquilimab in CSU.

●Jeet Mahal appointed as Chief Executive Officer to lead next phase of clinical growth.

●Reported positive updated data from briquilimab studies in chronic spontaneous urticaria in January 2026:

o67% of additional patients (n=6) enrolled in the BEACON study given an initial dose of 240mg briquilimab followed by 180mg every 8 weeks achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

o75% of CSU participants (n=36) enrolled in the open label extension dosed with 180mg briquilimab every 8 weeks achieved a complete response or well controlled disease at 12 weeks

oWith a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study

First Quarter Fiscal 2026 Financial Results

●Cash and cash equivalents as of March 31, 2026, totaled $14.1 million.

●Research and development expense for the three months ended March 31, 2026, was $5.8 million.

●General and administrative expense for the three months ended March 31, 2026, was $5.1 million.

●Jasper reported a net loss of $1.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.

About Jasper

Jasper is a clinical-stage biotechnology company

focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the KIT receptor, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently evaluating briquilimab as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma; Jasper’s continued advancement of its briquilimab development program in CSU; Jasper’s Phase 2b study in CSU, including the planned commencement thereof and the selection of dosing regimes; and Jasper’s work to secure additional funding for its Phase 2b study in CSU. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as,

EX-99.1

2 ea028336401ex99-1.htm

PRESS RELEASE, DATED MARCH 30, 2026

Exhibit 99.1

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

REDWOOD

CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update.

“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients. We are finalizing dose selection for the Phase 2b portion of our planned Phase 2b/3 study in CSU where we will evaluate two efficacious doses versus placebo to demonstrate the differentiated profile based on briquilimab’s unique biological properties. We remain on track to commence patient enrollment in the second half of 2026, pending capital availability.”

Highlights for Fourth Quarter 2025 and Recent Weeks

●Jeet Mahal appointed as Chief Executive Officer to lead next phase of clinical growth.

●Reported positive updated data from briquilimab studies in chronic spontaneous urticaria:

○67% of additional patients (n=6) enrolled in Cohort 9.1 (240mg/180mg Q8W) of the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points,

○75% of CSU participants (n=36) enrolled in the open label extension study (180mg Q8W) achieved a complete response or well controlled disease at 12 weeks,

○With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were predominantly low-grade events that resolved while on study, and

○BEACON

and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026.

●Announced the completion of the Company’s internal investigation into the anomalous lack of clinical response observed in the July 2025 BEACON data for cohort 8 (240mg Q8W) and cohort 9 (240mg/180mg Q8W). Results indicated there were no issues with the drug product utilized in the study, and the key opinion leader panel convened generated recommendations to enhance site selection and patient screening criteria going forward. Jasper’s internal investigation included:

○Switching all US patients to a new lot of drug product for the remainder of their doses on study to determine if drug product played a role,

○A comprehensive review of all manufacturing records, drug handling, site training/ logs and data handling,

○Recovery and testing by Jasper and independent labs of drug product samples from across the supply chain,

○A review of all US sites and all US patients, including protocol adherence patient medical histories, patient screening and all pharmacokinetics, pharmacodynamics and efficacy data, and

○Assembling a KOL panel to review the internal investigation findings, including full patient dossiers, which provided its input and conclusions from the findings.

●Reported positive preliminary data from ETESIAN study of briquilimab in asthma:

○Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study, and

○The positive proof of concept data generated in the ETESIAN study supports further development in the broader asthma population; however, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital availability.

Fourth Quarter Fiscal 2025 Financial Results

●Cash and cash equivalents as of December 31, 2025, totaled $28.7 million.

●Research and development expense for the three months ended December 31, 2025, was $11.4 million.

●General and administrative expense for the three months ended December 31, 2025, was $4.5 million.

●Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended December 31, 2025, respectively.

About Jasper

Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding